ISAC Modulation of Tumor Microenvironments to Enable Durable Antitumor Immunity

  • Characterizing the immune composition of preclinical tumor models and the therapeutic relevance to patient populations
  • Understanding mechanism of action-dependent relationships between antigen density and treatment efficacy demonstrates potential ISAC advantages over conventional antibody-drug conjugates in clinical translation
  • Tumor-targeted myeloid activation stimulates both innate and adaptive immune responses transforming immunologically cold tumors into hot microenvironments resulting in more durable responses